Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Inovio Pharmaceuticals (NASDAQ:INO) with a $40 price target.
March 08, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh reaffirms an Outperform rating on Inovio Pharmaceuticals with a $40 price target.
The reaffirmation of an Outperform rating and a $40 price target by a reputable analyst like Hartaj Singh suggests a strong vote of confidence in Inovio Pharmaceuticals. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100